THE SIGNAL

Issue 004 - April 16, 2026 - TESTOSTERONE REPLACEMENT THERAPY (TRT)

THE SIGNAL — FeltovichFit
FeltovichFit

THE SIGNAL

Scientific Intelligence for Men's Health & Performance

A FeltovichFit Publication  ·  Collegium of Order & Flow

Week of April 12–17, 2026  ·  Issue 004  ·  Andy Feltovich, CISSN · CSCS · StrongFirst Elite

Each week, The Signal cuts through the noise in health, performance, and science:

  • What to watch?
  • What to ignore?
  • What’s “news” but isn’t new?

The Signal analyzes each topic with the IICE Framework:

  • Incentives.  Who is being asked to believe what? Why? And why now?
  • Impact.  Does it move the needle?
  • Context.  How does it relate to other evidence within the discipline and across disciplines, both currently and historically?
  • Epistemic Authority.  Is the argumentation sound and valid?

This week’s deep dive: Testosterone Replacement Therapy—the history, the risks, the real indications, and what the body’s own medicine cabinet can do first.


▶  What to Watch

Watch 1

GLP-1s: Tariffs and Orals

News Traffic
Two seismic events occurred in 48 hours. On April 1, the FDA approved Eli Lilly’s Foundayo™ (orforglipron)—the first oral small-molecule GLP-1 receptor agonist approved for obesity management—requiring no refrigeration, no injection, and no food or water restriction. Participants in the ATTAIN-1 trial (n=3,127) lost an average of 27 lbs (12.4% body weight) on the highest dose, at a self-pay cost of $149–$349/month or $25/month for insured patients. On April 2, the White House issued a Section 232 proclamation imposing 100% tariffs on imported pharmaceuticals, with a 20% reduced rate for companies with onshoring agreements (escalating to 100% over four years) and 0% through 2029 for companies that agreed to Most Favored Nation (MFN) pricing.

The Signal
The oral story is simple: an effective oral medication will convert the remaining holdouts for whom the deal-breaker was needles and injections.


Tariffs, a more nuanced topic, usually follow a predictable pattern: disruptions and price volatility in the short term that settles to steadier, modestly higher prices in the longer term. Industries dislike higher supply prices—but they hate surprises. Once the initial shock of the tariffs subsides, what usually happens is the different actors along the supply chain start to absorb the increased costs—so they’re not all borne by consumers—and higher supply prices increase competition among existing suppliers, bring new suppliers into the market, and inspire creative substitution for alternatives that aren’t affected by the tariffs—all of which act to counter the effects of the initial tariffs and reduce prices.


The lean mass problem is unchanged—roughly 40% of weight lost on GLP-1 therapy is lean mass. Structured resistance training and adequate protein are mandatory adjuncts. See Issue 003 Deep Dive for the full protocol.

Headlines
Reuters, Apr 1, 2026 · CNBC, Apr 1, 2026 · Fierce Pharma, Apr 1, 2026 · White House Section 232, Apr 2, 2026

Watch 2

Sleep Apnea Pipeline: Apnimed and Sulthiame

News Traffic
Apnimed secured $150M in debt financing from Healthcare Royalty Partners on April 6 to support the planned commercial launch of AD109 (aroxybutynin + atomoxetine), with an NDA submission to FDA anticipated imminently according to their stated early-2026 timeline. Fast Track designation (granted 2022) puts the earliest FDA decision at late 2026 or early 2027. Separately, The Lancet published Phase 2 data on sulthiame—a carbonic anhydrase inhibitor already approved in Europe for childhood epilepsy—showing up to 47% reduction in AHI (apnea-hypopnea index) in moderate-to-severe OSA, nearly identical to AD109’s Phase 3 efficacy numbers.

The Signal
Sleep apnea has been recognized as the killer that it is—no need to belabor the point here. The problem has been adherence to the most common treatment, CPAP, a bulky mechanical device which many patients find cumbersome and uncomfortable—not to mention the added difficulties of travel. Medications reduce that barrier. Given the prevalence of sleep apnea in 35+ year-old male professionals—estimated at 25–30% of middle-aged men, with rates likely higher in this cohort—and the ease of pharmacological interventions relative to CPAP, expect penetration in this market to increase sharply. Pharmacological treatment is currently almost non-existent due to lack of approved medications.


This is a huge step towards viable pharmacological interventions for sleep apnea: two drugs, two distinct pharmacological mechanisms, nearly identical efficacy–the first departure from the weight loss, CPAP, or nothing approach of the last 30 years.


If you snore, wake unrefreshed, or have a partner reporting frequent sleep disturbances, see your primary care physician. He can usually conduct questionnaires such as the STOP-BANG or the Insomnia Severity Index and refer you to a board-certified sleep physician if necessary (see The Signal Podcast episode with Dr. Muhammad Usama for details—and never try to diagnose or treat sleep apnea on your own).

Headlines
Apnimed / PR Newswire, Apr 6, 2026 · Apnimed Phase 3 Results · The Lancet, Sulthiame Phase 2, Mar 2026 · U.S. News, Mar 12, 2026


✕  What to Ignore

Ignore 1

GLP-1s: NAION MDL

News Traffic
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)—a form of sudden vision loss caused by reduced blood flow to the optic nerve—is the subject of a growing Multidistrict Litigation (MDL) against Novo Nordisk, now at approximately 3,546 consolidated cases. NAION was identified as a potential risk in a 2024 JAMA Ophthalmology study and resulted in European label updates. Coverage has intensified with the case count.

The Signal
This was predictable—maybe not this specific side effect—but some rare side effect that only manifests after release and widespread use. Pre-release clinical trials are powered to detect side effects occurring in roughly 1 in 100 patients or more; anything rarer requires large post-market surveillance databases to detect reliably. The increase in absolute risk is modest: NAION incidence rises from approximately 1 in 10,000 per year to approximately 2 in 10,000 per year. The American Academy of Ophthalmology (AAO) recommends a pre-treatment dilated eye exam and annual follow-up to mitigate this risk. That is the actionable item—not the MDL case count.


A larger structural issue is the perverse incentives in the U.S. for hiding side effects that manifest after a drug’s release. Pharma companies have an obvious incentive to downplay post-release side effects, but so does the FDA. The functions that approve and monitor drugs are nominally separate—the Office of New Drugs (which approves) and the Office of Pharmacovigilance and Epidemiology (which monitors)—but they ultimately both fall under The Center for Drug Evaluation and Research (CDER): same roof, same leadership chain, same congressional budget. The European Medicines Agency handles this more cleanly, with a dedicated pharmacovigilance committee (PRAC) that operates independently of the approval committee—which is why the EMA updated the semaglutide label for NAION in 2024 while the FDA has moved more slowly.

Headlines
Motley Rice MDL Update, Apr 2026 · JAMA Ophthalmology, Hathaway et al., 2024 · EMA NAION Ruling, 2024

Ignore 2

Peptides and Biohacking

News Traffic
Social media coverage of peptide therapy continues to expand. RFK Jr. announced in February that 14 of 19 previously restricted peptides—including BPC-157, TB-500, CJC-1295, and GHK-Cu—would return toward legal compounding status. No formal FDA rule change has occurred.

The Signal
First, the RCTs demonstrating the safety and efficacy of most of the rapidly proliferating modern peptides in healthy adult males would fit in a thimble—and that’s in addition to the issues of manufacturing quality and third-party testing for products purchased outside a licensed compounding pharmacy.


A few peptides show promise and are ripening for serious clinical consideration—Thymosin alpha-1 and BPC-157 are the most credible sub-stories—but I don’t know any serious professional with actual skin in the game who is pushing them currently.


The bigger story that everyone gets wrong is that peptide-friendly regulation is around the corner, or that RFK Jr.’s overtures to peptide proponents are going to change anything materially. Regulatory reform happens at the speed of Washington, so nothing was going to happen in the short term anyway. In the longer term, RFK Jr. is out in the next administration, and his successor is unlikely to carry this torch. In short: dead on arrival.

See LinkedIn post for details.

Headlines
Swagger Magazine, Mar 23, 2026 · Victory Men’s Health, Mar 26, 2026

Old Stories

Covered in Issue 003 — Still Dying Their Slow, Rightful Death

These were covered in depth in Issue 003 and nothing material has changed.

  • RFK / Food Dyes: Political deceleration complete; no new adult science. If you eat real food, this problem does not exist for you.
  • Cold Plunge / Ice Bath: Removal watch—narrative fully normalized, no new signal. Sequencing settled: never cold immediately after lifting.
  • Slow Wellness / Over-Optimization Backlash: Removing from dashboard. The underlying physiology of parasympathetic regulation is real—the product being sold is not.

↻  What’s “News” but Isn’t New

Not New 1

Testosterone, Microplastics, and Knee Surgery Complications

News Traffic
A Nature Scientific Reports study (February 23, 2026) mapped the molecular mechanism by which polystyrene microplastics impair testosterone production: dose-dependent suppression of PGC-1α and TFAM, impairing mitochondrial function in Leydig cells and reducing steroidogenesis. Separately, a Karolinska dataset found elevated thromboembolic complication rates in men on TRT undergoing knee replacement surgery.

The Signal
Plastics proliferated widely in the mid-twentieth century with little prior thought given to their long-term health consequences. To be fair, endocrinology and toxicology were still in their relative infancy. Plastics rely on BPA and phthalates for many of their desirable properties: rigidity, clarity, durability. Those are now known endocrine-disrupting compounds (EDCs). See the Deep Dive below for details and the full environmental optimization protocol.


The knee-replacement story is noise. Thrombosis—blood clots—is a possible complication from any major surgery. TRT can raise hematocrit, which is why hematocrit is part of routine ongoing monitoring for patients undergoing TRT. Cessation prior to elective surgery—especially if elevated hematocrit is detected—is an effective mitigant for this risk. Disclose TRT to your surgical team. Cessation prior to surgery—especially if elevated hematocrit is detected—is an effective mitigant. Confirm hematocrit is within range before proceeding.

Headlines
Nature Scientific Reports, Feb 23, 2026 · WYPR / NPR, Dec 12, 2025 · STAT News, Jan 12, 2026

Old Stories

Covered in Prior Issues

Gut Microbiome and Cognition
See Issue 003.

Protein, Sarcopenia, and Anabolic Resistance
See Issue 003 Deep Dive. The Foundayo approval makes the lean mass adjunct protocol more urgent than ever for anyone on GLP-1 therapy.

Sauna / Heat Therapy
A new study out of the University of Turku in Finland found some potential beneficial effects on white blood cells and immunity, but it is an additional puzzle piece that does not change the underlying thesis covered previously. See Issue 002 Deep Dive.

Headlines: University of Turku, Apr 9, 2026

VO₂ Max
This hasn’t changed since the last issue—or much in the past 50 years for that matter. The bloom is coming off the VO₂ max rose in tandem with the bloom coming off its primary advocate, fallen longevity demigod Peter Attia. Studies and influencers extolling the virtues of VO₂ max almost invariably conflate numerous measures of cardiorespiratory fitness (CRF) and VO₂ max. More consequentially, they distract from easier-to-measure and more impactful performance metrics like anaerobic threshold—work capacity prior to going anaerobic.


Wearables purporting to measure VO₂ max are a full-stop no-go—the physiometric equivalent of looking into a crystal ball.


See Issue 003. This is ripening for a Deep Dive.


■  Deep Dive—Issue 004

Testosterone Replacement Therapy: History, Risks, Real Indications, and the Body’s Own Medicine Cabinet

The magic of whatever lay within the testes and its role in male traits and reproduction has been known since humans first castrated animals approximately 10,000 years ago to make them sterile, docile, or alter their bodies, and men were castrated and made eunuchs to guard royal households and harems as early as the Chinese Xia dynasty in 2205 BCE [1].

The magic itself—testosterone—was first isolated, named, and synthesized in 1935 and soon found clinical and non-clinical uses: first in therapeutic doses to treat anemia, depression, angina, peripheral vascular disease, and hypogonadism (then termed “male climacteric” or “male menopause”), then in supratherapeutic doses for physique and performance enhancement [2].

Several beneficial effects of TRT were soon observed, including improved mood, libido, and body composition. One result was also observed—and misinterpreted—which effectively brought a halt to TRT for seven decades. A 1941 experiment treated men with metastatic prostate cancer using castration and high-dose estrogens and observed sharp falls in a tumor marker of the day (acid phosphatase), which they interpreted as evidence that withdrawing androgens shrank prostate cancer. The same paper—with a sample size of just three men—reported an increase in acid phosphatase after short courses of testosterone propionate injections and generalized that observation into the conclusion that exogenous testosterone “activates” prostate cancer in hypogonadal men without cancer [2].

That narrative prevailed until the 1970s when radioimmunoassay made laboratory testing cheap and accurate enough to study large cohorts. The resulting data over the following decades showed that men with chronically low testosterone had higher all-cause mortality, more cardiovascular disease, more low-trauma fractures, and worse cardiometabolic profiles than eugonadal men [2]. The downside risks have since skewed toward not doing TRT in hypogonadal men, but risks remain, and not every symptomatic man is a candidate for TRT.

Real Risks and Real Tradeoffs

Like any powerful drug, there are real risks, costs, and tradeoffs:

  • TRT can increase hematocrit (red blood cell count), a potential risk factor for thrombosis (blood clots). Most guidelines recommend checking hematocrit regularly and pausing TRT if it exceeds established thresholds [3]. Men undergoing elective surgery while on TRT should disclose this to their surgical team; cessation prior to surgery—especially if elevated hematocrit is detected—is an effective mitigant.
  • TRT can suppress sperm production and cause sterility. Fertility usually returns after cessation, but timing is variable and return is not guaranteed [4, 5].
  • Although the “testosterone activates prostate cancer” myth has been debunked for men without known cancer, men with active prostate cancer, suspicious prostate findings, very high PSA, or severe lower urinary tract symptoms are generally advised to avoid TRT or proceed only with urologic evaluation and close monitoring [6].
  • TRT is generally avoided or used cautiously in men with severe untreated obstructive sleep apnea [3]. Much of the early data linking TRT with worsening sleep-disordered breathing was based on supratherapeutic doses, but caution remains prudent [7].
  • TRT can also cause acne, oily skin, gynecomastia, injection-site reactions, and in some men raise PSA modestly even without cancer—which is why ongoing lab and symptom monitoring is recommended [8].

Unfounded Fears

Along with those real risks, there are unfounded fears—most notably alopecia (male pattern baldness). Alopecia is mostly determined by genetic sensitivity to dihydrotestosterone (DHT), a testosterone byproduct. TRT might accelerate balding but is unlikely to cause it in men who were not already genetically predisposed [9]. The data suggesting accelerated hair loss were based largely on supratherapeutic doses, so therapeutic doses may pose less risk. Drugs to counteract alopecia—dutasteride or finasteride (e.g., Propecia)—work by inhibiting conversion of testosterone to DHT, [10] which could blunt some DHT-mediated processes, including those that TRT is trying to remedy.

The Body’s Own Medicine Cabinet

Before resorting to pharmaceuticals to remedy hypogonadism—or any other pathology—lifestyle and environmental optimization should always be the first line of defense.

Empirically validated factors to promote healthy testosterone production include:

  • Sleep, sleep, sleep. Sleep deprivation decreases testosterone approximately 10–15% in short-term studies [7], the functional equivalent of adding a decade of age to a man’s testosterone profile [11].
  • Body composition and energy optimization. Excess body fat can decrease testosterone directly and increase estrogen via aromatization of testosterone to estradiol [3]. It can also decrease testosterone indirectly through disrupted sleep [7], but low energy availability through very low body fat or hypocaloric diets can decrease testosterone too [12].
  • Nutrition. Suboptimal levels of vitamin D, zinc, or magnesium can limit testosterone production, but benefits plateau once sufficient levels are achieved [12].
  • High-volume resistance training with compound movements [13]. The effects are likely more transient and less impactful in total than the previous three drivers, but it is still an effective lever—and something all men should be doing regardless.

Environmental Toxins

The known environmental toxins that impair testosterone production, grouped by type and severity, include [14]:

  • Hormone mimetics and blockers (endocrine-disrupting chemicals, EDCs)—mostly BPA and phthalates from plastics and parabens from cosmetics—moderate risk
  • Persistent endocrine disruptors—mostly agricultural and industrial chemicals such as herbicides, pesticides, and PCBs—moderate to high risk
  • Direct cellular toxins—mostly heavy metals such as lead, mercury, and cadmium—high risk
  • Bioaccumulating hormone disruptors (persistent organic pollutants, POPs)—such as dioxins and flame retardants (PBDEs). PCBs also fit here—low risk from acute exposure that accumulates to moderate risk from chronic exposure
  • Systemic inflammatory toxins—mostly particulate air pollution such as smoke, exhaust, and urban air pollution—moderate to high risk

To optimize the environment: avoid plastics by filtering water and by not storing or heating food in them. Use paraben-free cosmetics. Buy organic food when practical and economical, especially in the U.S. As Nathan notes on pesticide use in the U.S.:

Twenty-five of these pesticides [used in the U.S.] are banned in more than thirty other countries. Phorate, the most used ‘extremely hazardous’ insecticide in the U.S., is banned in thirty-eight other countries, including China, Brazil, and India. None of the ‘extremely hazardous’ pesticides we use here in the U.S. can be used in the twenty-seven nations of the European Union [15].

Avoid flame retardants by using natural fabrics like wool or cotton instead of synthetic fabrics—including synthetic carpets—or use materials that don’t burn: brick, stone, metal, glass. For air pollutants and particulate matter, a HEPA air filter in the bedroom and a MERV 13+ HVAC system are the biggest levers, as are avoiding burning candles and incense. And of course avoid heavy metals, including by moderating consumption of tuna, shark, swordfish, king mackerel, and tilefish [16].

Optimizing immunity is sufficient for incidental exposure to most common environmental toxins (see LinkedIn post and Substack article). True toxicity in which the body’s detoxification machinery is insufficient for the task is rarer than the “detox” industry would have you believe. When it does occur, the patient is usually very sick and should be treated by a professional.

Myths Worth Dispelling

With environmental toxins, a couple of myths are worth dispelling. The first concerns “female hormones” and their mimetics (xenoestrogens) in soy products and in the water supply from contraceptive pills being flushed down toilets—both of which have been safely exonerated as culprits [17, 18]. The emerging data on microplastics cannot be dismissed as easily. There are credible mechanisms for hormone disruption [19, 20], but the population data remain at the level of correlational epidemiology [21]. It is concerning and worth monitoring, but testosterone decline at the population level is likely better explained by the behavioral and lifestyle factors mentioned above.

Diagnostics: When to Consider TRT

After optimizing lifestyle and environment and ruling out contraindications, the decision to pursue TRT comes down to a combination of lab results, symptoms [3, 8], and personal cost-benefit analysis.

The standard diagnostic criteria begin with two lab tests below 300 ng/dL on two separate mornings. The standard test measures all three forms of testosterone:

  • Testosterone bound by Sex Hormone-Binding Globulin (SHBG), a transporter and regulator protein—not immediately bioavailable
  • Testosterone bound by albumin—considered loosely bound and bioavailable
  • Free testosterone—the most bioavailable form

If total testosterone is borderline or if SHBG levels are abnormal, additional tests may be warranted: free testosterone, luteinizing hormone (LH), or follicular stimulating hormone (FSH)—the latter two being intermediate signaling hormones that precede testosterone synthesis.

The other diagnostic criteria are symptom-based: mood changes, decreased libido, erectile dysfunction, fatigue, reduced muscle mass and strength, or increased body fat.

Forms of TRT

Once the decision to pursue TRT has been made, the next question is which form to use. The most common options, each with its pros and cons, include [22]:

Short-duration intramuscular injectables (testosterone cypionate or enanthate)

  • Pros: cost-effective and flexible
  • Cons: serum testosterone peaks at 24–72 hours then declines gradually over approximately two weeks, which can lead to fluctuations in mood, performance, and hematocrit

Transdermal gels or creams

  • Pros: more consistent, stable delivery
  • Cons: require daily application and risks exposing others: children, pets, partners

Transdermal patches

  • Pros: consistent delivery, shares the advantages of gels and creams
  • Cons: requires daily application and can cause skin irritation—generally not advised

Oral pills

  • Pros: convenient
  • Cons: must be consumed with fat and has variable bioavailability. Formulations are getting safer but hepatotoxicity (liver toxicity) remains a risk—generally not advised.

Long-duration injectables

  • Pros: less frequent injections than short-duration injectables
  • Cons: less flexibility than short-duration injectables and small risk of pulmonary oil microembolisms

Pellets (inserted subcutaneously, releasing testosterone over several months)

  • Pros: infrequent administration and steady release
  • Cons: can be expensive, cause irritation at the insertion site, and occasionally be extruded from the body

Regardless of formulation, TRT suppresses natural testosterone and sperm production, which can reduce fertility and decrease testicular volume. Human chorionic gonadotropin (hCG) can be used in addition to or in lieu of TRT to help preserve natural testosterone production, sperm production, and testicular volume.

The Decision

If you recognize these symptoms and lifestyle and environmental interventions have failed to remedy the problem, talk with your physician. If he dismisses TRT outright, get a second opinion. Dogmatic opposition by ostensible medical professionals not only ignores substantial evidence of TRT’s ability to improve health outcomes—it is contrary to their duty to treat disease. Hypogonadism is a disease state. The hypothalamic-pituitary-gonadal (HPG) axis is damaged or otherwise not producing healthy levels of testosterone for whatever reason: age, injury, etc. The “R” in “TRT” stands for “Replacement”—replacing what is absent in the diseased state to return the patient to health.

Conversely, if your physician reflexively recommends TRT—or worse—immediately farms you out to a TRT clinic (“mills” to use the often-deserved sobriquet)—possibly one in which he has a financial interest—also get a second opinion. TRT offers tremendous potential benefits for the right candidate, but it shouldn’t be entered into lightly—nor should it be done to finance your doctor’s country club membership.

The IICE Read: The misconceptions about the dangers of TRT and prostate cancer stem largely from the results of three research subjects in a 1941 study. The evidence since then is overwhelming in the opposite direction: TRT in hypogonadal men without prostate cancer reduces several causes of mortality while increasing performance, mood, and libido. However, like all powerful drugs, there are risks and tradeoffs. Ensure that you don’t have contraindications that would preclude safe use of TRT prior to beginning treatment, and continue to monitor while undergoing TRT. The form of TRT matters too (injectables, pills, pellets, creams, etc.). Talk through all the options with your doctor. Beware of TRT mills that are more interested in your money than your health.

■  References · Further Reading · Additional Resources

References — Issue 004 Deep Dive

[1] A. Morgentaler and H. M. Hanafy, “The testis, eunuchs, and testosterone: a historical review over the ages and around the world,” Sex Med Rev, vol. 12, no. 2, pp. 199–209, Mar. 2024. doi: 10.1093/sxmrev/qead051

[2] A. Morgentaler and A. Traish, “The History of Testosterone and the Evolution of its Therapeutic Potential,” Sexual Medicine Reviews, pp. 1–11, 2018. doi: 10.1016/j.sxmr.2018.03.002

[3] S. Bhasin et al., “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline,” J. Clin. Endocrinol. Metab., vol. 103, no. 5, pp. 1715–1744, 2018. doi: 10.1210/jc.2018-00229

[4] W. J. G. Hellstrom (Ed.), Androgen Deficiency and Testosterone Replacement: Current Controversies and Strategies. Humana Press, 2013.

[5] A. Majzoub and E. Sabanegh Jr., “Testosterone replacement in the infertile man,” Transl. Androl. Urol., vol. 5, no. 6, pp. 859–865, 2016. doi: 10.21037/tau.2016.08.03

[6] L. Boeri et al., “Testosterone Therapy in Adult Males with Hypogonadism,” Eur. Urol., 2025. doi: 10.1016/j.eururo.2025.12.015

[7] M. H. Kryger, T. Roth, and C. A. Goldstein, Kryger’s Principles and Practice of Sleep Medicine, 7th ed. Philadelphia: Elsevier, 2022.

[8] J. P. Mulhall et al., “Evaluation and Management of Testosterone Deficiency: AUA Guideline,” J. Urol., vol. 200, no. 2, pp. 423–432, 2018. doi: 10.1016/j.juro.2018.03.115

[9] W. Tawanwongsri et al., “Hair loss in athletic testosterone use in males: a narrative review,” Int. J. Dermatol., vol. 64, pp. 654–658, 2025. doi: 10.1111/ijd.17567

[10] P. M. Zito, K. G. Bistas, P. Patel, and K. Syed, “Finasteride,” in StatPearls. Treasure Island, FL: StatPearls Publishing, 2024.

[11] B. Marcello, “Sleep – The Only True ‘Fix-All’ for Health and Performance,” NSCA, May 15, 2020. YouTube

[12] S. S. Gropper, J. L. Smith, and T. P. Carr, Advanced Nutrition and Human Metabolism, 8th ed. Cengage Learning, 2022.

[13] M. Greenwood et al., Nutritional Supplements in Sports and Exercise, 2nd ed. Springer International Publishing, 2015.

[14] C. D. Klaassen, Casarett and Doull’s Toxicology: The Basic Science of Poisons, 9th ed. McGraw-Hill Education, 2019.

[15] N. Nathan, The Sensitive Patient’s Healing Guide, 1st ed. Cypress House, 2024.

[16] U.S. Food and Drug Administration and U.S. Environmental Protection Agency, “FDA/EPA 2004 Advice on What You Need to Know About Mercury in Fish and Shellfish,” updated 2021. FDA.gov

[17] K. E. Reed et al., “Neither soy nor isoflavone intake affects male reproductive hormones: An expanded and updated meta-analysis,” Reprod. Toxicol., vol. 100, pp. 60–67, 2021. doi: 10.1016/j.reprotox.2020.12.019

[18] American Chemical Society, “New report: Don’t blame The Pill for estrogen in drinking water,” 2011. ACS.org

[19] M. Karimian and S. Yaqubi, “Microplastics and male reproductive system: A comprehensive review based on cellular and molecular effects,” Toxicol. Rep., vol. 16, p. 102226, 2026. doi: 10.1016/j.toxrep.2026.102226

[20] S. Ullah et al., “A review of the endocrine disrupting effects of micro and nano plastic and their associated chemicals in mammals,” Front. Endocrinol., vol. 13, 2023. doi: 10.3389/fendo.2022.1084236

[21] C. Zhang et al., “Association of mixed exposure to microplastics with sperm dysfunction: a multi-site study in China,” eBioMedicine, vol. 108, p. 105369, 2024. doi: 10.1016/j.ebiom.2024.105369

[22] L. L. Brunton and B. C. Knollmann, Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 14th ed. McGraw Hill, 2023.

Further Reading

► W. J. G. Hellstrom (Ed.), Androgen Deficiency and Testosterone Replacement: Current Controversies and Strategies. Humana Press, 2013.
This is the single best scientific, academic text on hypogonadism and TRT, the clinical reference for practitioners, dense and authoritative.
Hardcover   Paperback   Kindle

► S. S. Gropper, J. L. Smith, and T. P. Carr, Advanced Nutrition and Human Metabolism, 8th ed. Cengage Learning, 2022.
This is another dense and authoritative advanced text, the go-to reference for general nutrition and metabolism.
Hardcover   Kindle

► M. Greenwood et al., Nutritional Supplements in Sports and Exercise, 2nd ed. Springer International Publishing, 2015.
This is the foundational text for the Certification of the International Society of Sports Nutrition (CISSN), the gold standard in sports nutrition certifications. It focuses on nutrition and ergogenic aids from the standpoint of performance.
Hardcover   Paperback   Kindle

► C. D. Klaassen, Casarett and Doull’s Toxicology: The Basic Science of Poisons, 9th ed. McGraw-Hill Education, 2019.
This is the standard graduate textbook on toxicology.
Hardcover   eTextbook

► N. Nathan, The Sensitive Patient’s Healing Guide, 1st ed. Cypress House, 2024.
Dr. Nathan was the inspiration for adding Environment to the SCREEN Framework: Spirituality, Cognition, Recovery, Environment, Exercise, and Nutrition. He does some of the best work on environmental toxicity and treating toxicity.
Paperback   Kindle   Audible

► N. Nathan, Toxic. Victory Belt Publishing, 2025.
This is Dr. Nathan’s other major work, which focusses more on environmental toxins and their impact and less on treatment.
Paperback   Audible

► M. H. Kryger, T. Roth, and C. A. Goldstein, Kryger’s Principles and Practice of Sleep Medicine, 7th ed. Elsevier, 2022.
This is the standard clinical text on sleep medicine.
Hardcover   Kindle

Additional Resources

The Signal Podcast with Dr. Arny Ferrando—TRT, protein, and men’s aging. The companion interview to this issue’s Deep Dive.

The Signal Podcast with Dr. Muhammad Usama—Sleep as a Superpower. Sleep is the highest-leverage lifestyle intervention for testosterone. This is where to start.

Immunity Optimization—LinkedIn. Sufficient for incidental exposure to most common environmental toxins.

Pretox: Stronger Immunity and the Body’s Own Detox System—Substack.

Peptides and FDA: The Real Story—LinkedIn.

FDA/EPA Mercury in Fish Advisory—Full species-by-species mercury concentration table. Updated 2021.

Additional Resources—Social & Handles

Instagram: @FeltovichFit

FeltovichFit Podcast—Spotify

X: @FeltovichFit

Substack: @FeltovichFit

LinkedIn: FeltovichFit

YouTube: @FeltovichFit

Facebook: Andy Feltovich

■  Glossary of Terms & Acronyms

AHI—Apnea-Hypopnea Index—the standard clinical measure of sleep apnea severity (breathing interruptions per hour)

API—Active Pharmaceutical Ingredient—the biologically active substance in a drug product; counterfeit GLP-1 operators have been found supplying unapproved or misrepresented APIs

CPAP—Continuous Positive Airway Pressure—current standard-of-care device for obstructive sleep apnea; notoriously poorly adhered to

DHT—Dihydrotestosterone—a potent androgen derived from testosterone via 5-alpha reductase; mediates hair loss in genetically predisposed men; finasteride/dutasteride inhibit its production

EDC—Endocrine-Disrupting Chemical—compounds (including BPA, phthalates, and parabens) that interfere with hormone signaling

Foundayo™—Eli Lilly’s brand name for orforglipron; first oral small-molecule GLP-1 receptor agonist approved for obesity management; approved April 1, 2026

FSH—Follicle-Stimulating Hormone—pituitary hormone that stimulates sperm production; suppressed by exogenous testosterone

GLP-1—Glucagon-Like Peptide-1—a gut-derived hormone regulating appetite and blood sugar; the mechanism behind semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo)

hCG—Human Chorionic Gonadotropin—used adjunctively with TRT to preserve natural testosterone production, sperm production, and testicular volume

HPG axis—Hypothalamic-Pituitary-Gonadal axis—the hormonal signaling cascade that regulates testosterone production; impaired in hypogonadism

Hypogonadism—clinical deficiency of testosterone; defined by two morning measurements below 300 ng/dL plus symptoms; a disease state, not a lifestyle choice

IICE—Incentives, Impact, Context, Epistemic Authority—The Signal’s analytical framework for evaluating health claims

LH—Luteinizing Hormone—pituitary hormone that signals Leydig cells to produce testosterone; used diagnostically in TRT workup

MDL—Multidistrict Litigation—consolidated federal court process for mass tort cases; NAION GLP-1 cases are consolidated in an MDL

MFN—Most Favored Nation—pricing mechanism; the White House is seeking MFN drug pricing from pharma as a tariff concession

NAION—Non-Arteritic Anterior Ischemic Optic Neuropathy—vision-loss condition associated with semaglutide at approximately 2/10,000/year vs. ~1/10,000 background rate

NDA—New Drug Application—the formal submission a pharmaceutical company makes to the FDA to obtain approval for a new drug; the filing initiates the FDA’s review clock (6–10 months depending on designation)

orforglipron—small-molecule GLP-1 receptor agonist; non-peptide; marketed as Foundayo™ by Eli Lilly

OSA—Obstructive Sleep Apnea

PBDE—Polybrominated Diphenyl Ethers—flame retardants found in synthetic fabrics and carpets; persistent endocrine disruptors

PSA—Prostate-Specific Antigen—protein produced by prostate tissue; monitored during TRT; TRT can modestly raise PSA even without cancer

RCT—Randomized Controlled Trial—the highest-quality study design for establishing causality

Section 232—national-security-based trade authority used to impose pharmaceutical tariffs on April 2, 2026; harder to challenge legally than Section 301 tariffs

SHBG—Sex Hormone-Binding Globulin—protein that binds testosterone and reduces its bioavailability; high SHBG can mean total testosterone looks normal while free testosterone is low

sulthiame—carbonic anhydrase inhibitor approved in Europe for childhood epilepsy; Lancet Phase 2 data showed ~47% AHI reduction in moderate-to-severe OSA

TRT—Testosterone Replacement Therapy


Collegium of Order & Flow

Collegium of Order & Flow

Frameworks for a Fallen World

“In the age of AI, siloed thinkers are obsolete. Systems-and-design thinkers are preeminent.”

ΠΑΝΤΑ ΡΕΙ  —  Everything Flows

THE SIGNAL is produced by Andy Feltovich—CISSN · CSCS · StrongFirst Elite
A FeltovichFit Publication  ·  Collegium of Order & Flow  ·  Not medical advice.

Get THE SIGNAL Weekly